These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 19594773)

  • 1. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients.
    Badowski M; Gurk-Turner C; Cangro C; Weir M; Philosophe B; Klassen D; Haririan A
    Clin Transplant; 2009; 23(6):930-7. PubMed ID: 19594773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
    Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation.
    Freise CE; Kang SM; Feng S; Posselt A; Hirose K; Hirose R; Stock P
    Transplant Proc; 2004 May; 36(4):1067-8. PubMed ID: 15194370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients.
    Yeung S; Tsang WK; Tong KL; Wong SH; Lee W; Tang HL; Chan HW; Chan AY
    Transplant Proc; 2004 Sep; 36(7):2084-6. PubMed ID: 15518754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Freedom from graft vessel disease in heart and combined heart- and kidney-transplanted patients treated with tacrolimus-based immunosuppression.
    Groetzner J; Kaczmarek I; Mueller M; Huber S; Deutsch A; Daebritz S; Arbogast H; Meiser B; Reichart B
    J Heart Lung Transplant; 2005 Nov; 24(11):1787-92. PubMed ID: 16297783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid elimination in simultaneous liver-kidney transplantation recipients.
    Weber NK; Wiseman AC; Trotter JF
    Clin Transplant; 2009; 23(6):958-63. PubMed ID: 19664017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
    Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
    Stratta RJ; Alloway RR; Lo A; Hodge E
    Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rejection after simultaneous pancreas-kidney transplantation.
    Arbogast H; Malaise J; Illner WD; Tarabichi A; Dieterle C; Landgraf R; Land W;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii11-7, ii62. PubMed ID: 15814544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C.
    Luan FL; Schaubel DE; Zhang H; Jia X; Pelletier SJ; Port FK; Magee JC; Sung RS
    Transplantation; 2008 Jun; 85(11):1601-6. PubMed ID: 18551066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of age on patient tolerance of mycophenolate following kidney transplantation.
    Rennie TJW; Petrie M; Metcalfe W; Walbaum D; Joss N; Barton E; Marson L; Clancy MJ; Henderson L; Traynor JP; Geddes CG; Phelan PJ
    Nephrology (Carlton); 2020 Jul; 25(7):566-574. PubMed ID: 32323461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients.
    Cena T; Musetti C; Quaglia M; Magnani C; Stratta P; Bagnardi V; Cantaluppi V
    Transpl Int; 2016 Oct; 29(10):1085-93. PubMed ID: 27343849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excessive immunosuppression in kidney transplant patients: prevalence and outcomes.
    Sanders-Pinheiro H; da Silveira ST; Carminatti M; Braga LS; Marsicano EO; Magalhães GL; Carvalho LF; Filho GF; Magacho EJ; Colugnati F; Bastos MG
    Transplant Proc; 2012 Oct; 44(8):2381-3. PubMed ID: 23026599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.